-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
NewAmsterdam Pharma (NASDAQ:NAMS) Expected to Post FY2027 Earnings of ($0.16) Per Share
NewAmsterdam Pharma (NASDAQ:NAMS) Expected to Post FY2027 Earnings of ($0.16) Per Share
NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Equities research analysts at William Blair issued their FY2027 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a report issued on Monday, January 23rd. William Blair analyst M. Phipps forecasts that the company will earn ($0.16) per share for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is $0.27 per share.
Get NewAmsterdam Pharma alerts:NAMS has been the subject of a number of other research reports. SVB Leerink began coverage on NewAmsterdam Pharma in a report on Tuesday, December 20th. They issued an "outperform" rating and a $19.00 price target for the company. Jefferies Financial Group initiated coverage on NewAmsterdam Pharma in a report on Monday, December 19th. They issued a "buy" rating and a $24.00 price target for the company. Finally, Credit Suisse Group initiated coverage on NewAmsterdam Pharma in a research report on Friday, January 6th. They issued an "outperform" rating and a $21.00 target price on the stock.
NewAmsterdam Pharma Price Performance
NASDAQ NAMS opened at $11.30 on Thursday. NewAmsterdam Pharma has a fifty-two week low of $7.52 and a fifty-two week high of $32.88. The business has a 50 day moving average of $10.29.NewAmsterdam Pharma Company Profile
(Get Rating)
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events.
Read More
- Get a free copy of the StockNews.com research report on NewAmsterdam Pharma (NAMS)
- Mergers and Acquisitions in 2023 Off To A Strong Start
- What Does Apple's Move to India Mean for Investors?
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Equities research analysts at William Blair issued their FY2027 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a report issued on Monday, January 23rd. William Blair analyst M. Phipps forecasts that the company will earn ($0.16) per share for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is $0.27 per share.
新阿姆斯特丹製藥公司(NASDAQ:NAMS-獲得評級)— 威廉·布萊爾的股票研究分析師在 1 月 23 日星期一發布的報告中發布了新阿姆斯特丹製藥公司的 FY2027 每股收益(EPS)估計。威廉·布萊爾分析師 M· 菲普斯預測,該公司將在今年的每股賺取(0.16 美元)。威廉·布萊爾的股票評級為「跑贏大市」。新阿姆斯特丹製藥公司目前全年收益的共識估計為每股 0.27 美元。
NAMS has been the subject of a number of other research reports. SVB Leerink began coverage on NewAmsterdam Pharma in a report on Tuesday, December 20th. They issued an "outperform" rating and a $19.00 price target for the company. Jefferies Financial Group initiated coverage on NewAmsterdam Pharma in a report on Monday, December 19th. They issued a "buy" rating and a $24.00 price target for the company. Finally, Credit Suisse Group initiated coverage on NewAmsterdam Pharma in a research report on Friday, January 6th. They issued an "outperform" rating and a $21.00 target price on the stock.
NAMS 一直是許多其他研究報告的主題。SVB Leerink 開始覆蓋新阿姆斯特丹製藥公司在週二的報告, 12 月 20 日.他們為該公司發布了「跑贏大市」評級和 19.00 美元的目標價格。富瑞金融集團在 12 月 19 日(星期一)的一份報告中啟動了新阿姆斯特丹製藥公司的報導。他們為該公司發布了「購買」評級和 24.00 美元的目標價格。最後, 瑞士信貸集團開始覆蓋新阿姆斯特丹製藥公司在研究報告上週五, 1 月 6 日.他們發布了「跑贏大市」評級和 21.00 美元的股票目標價。
NewAmsterdam Pharma Price Performance
新阿姆斯特丹製藥價格表現
NewAmsterdam Pharma Company Profile
新阿姆斯特丹製藥公司簡介
(Get Rating)
(取得評分)
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events.
新阿姆斯特丹製藥公司 N.V. 是一家臨床階段的生物製藥公司,為患有低密度脂蛋白膽固醇(LDL-C)高風險的心血管疾病高風險患者開發口服非他汀類藥物。該公司的主要候選產品是 obicetrapib,這是一種口服,低劑量膽固醇酯轉移蛋白抑製劑,作為單一療法和 ezetimibe 的聯合療法,用於降低 LDL-C 並預防重大心血管不良事件的臨床試驗。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on NewAmsterdam Pharma (NAMS)
- Mergers and Acquisitions in 2023 Off To A Strong Start
- What Does Apple's Move to India Mean for Investors?
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- 獲取有關新阿姆斯特丹製藥公司(NAMS)的研究報告的免費副本
- 2023 年的合併和收購有利於一個強勁的開始
- 蘋果移居印度對投資者意味著什麼?
- AMD 仍然是最好的半導體股票之一
- 兩個紅利國王:約翰遜或雅培實驗室?
- 網絡安全股票的底部是什麼?
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收新阿姆斯特丹製藥日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關新阿姆斯特丹製藥公司及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧